SetPoint Medical appears in FDA records as the applicant for PMA P240039, filed November 4, 2024 and approved July 30, 2025, with the trade name SetPoint System and the generic name vagus nerve stimulator for rheumatoid arthritis. The approval order is signed by CDRH's Office of Neurological and Physical Medicine Devices, and the application carries product code SFJ with the Neurology advisory committee. The Summary of Safety and Effectiveness Data states that breakthrough device status was granted on March 15, 2024. Two later 30-Day Notice supplements, S003 and S004, address manufacturing and supplier process changes rather than new indications. [3][4][7]
The approved device and its components
The Prescriber Instructions for Use list three system parts with model numbers: Implant M01, Charger E04 and Docking Station C01. The same document gives a reorder manufacturer part number, SPM001, for the Implant. FDA's supplement record for S003 uses the trade name Charger SetPoint System and describes manufacturing changes to the Charger Litz Wire Cleaning method and the printed circuit board assembly. These records establish the documented hardware set without describing clinical performance. [2][5]
SetPoint Medical's own website describes the SetPoint System as a small, wireless, implantable device that stimulates the vagus nerve, and its therapy page describes a small integrated neurostimulator intended to activate immune pathways. Those characterizations come from the manufacturer's published pages, not from FDA's approval documents. [8][10]
Filing history and supplement scope
The original PMA was received November 4, 2024, amended February 28, 2025 and April 29, 2025, and approved July 30, 2025, with a Federal Register notice date of August 6, 2025 and docket number 25M-2963. The approval letter is addressed to Alexis Dineen, Vice President, Regulatory Affairs, at the Valencia, California address used in the filing. [3][7]
Supplement S003 was received September 18, 2026 and decided October 16, 2026 under decision code OK30, a 30-Day Notice for a process change affecting manufacturer, sterilizer, packager or supplier. Supplement S004 was received September 29, 2026 and decided October 29, 2026, also OK30, with an approval statement covering reduced endotoxin monitoring from every lot to quarterly sampling of at least one lot manufactured each quarter. Both supplements list the Neurology advisory committee and were not expedited. [1][2]
What the public record shows and does not show
The linked collection holds three PMA records as of the snapshot date: one original approval and two 30-Day Notices, with decision counts of two OK30 and one APPR. The smaller record sample of three rows carries the same counts. These figures describe the linked filings only and are not measures of sales, total portfolio or safety performance. No recall records appear in the sample. [1][2][3]
The Summary of Safety and Effectiveness Data notes that the applicant's manufacturing facility was inspected and found in compliance with the Quality System regulation in effect at the time, and that the revised Part 820, the Quality Management System Regulation, became effective February 2, 2026. The filing address in Valencia, California is a regulatory correspondence address in these records; no headquarters, ownership structure or parent company is verified in the numbered sources. [4]
